Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Net Cash Flow (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Net Cash Flow data on record, last reported at $71.5 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 59.39% year-over-year to $71.5 million; the TTM value through Sep 2025 reached -$244.4 million, down 184.93%, while the annual FY2024 figure was $262.7 million, 2619.0% up from the prior year.
  • Net Cash Flow reached $71.5 million in Q3 2025 per ZBIO's latest filing, up from -$152.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $176.2 million in Q3 2024 and bottomed at -$152.3 million in Q2 2025.
  • Average Net Cash Flow over 3 years is $5.4 million, with a median of -$17.5 million recorded in 2023.
  • The widest YoY moves for Net Cash Flow: up 59.39% in 2025, down 524.31% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at -$15.4 million in 2023, then tumbled by 163.43% to -$40.4 million in 2024, then surged by 276.91% to $71.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $71.5 million in Q3 2025, -$152.3 million in Q2 2025, and -$123.2 million in Q1 2025.